Replies to post #491117 on Anavex Life Sciences Corp (AVXL)

[tredenwater2]

The pps suppression makes me wonder if this is just solely pre revenue bullying or is this from MM’s and HF’s taking advantage of a “lock up” period between companies trying to to negotiate a partnership. One or the other is giving the Mm’s cart blanch over pushing the pps where ever the wind blows.

One day it will stop, the clouds will part and the 4% ers will fade away.

[falconer66a]

What, Then, Would Be the Dividend Payouts?

...$30 billion or so in revenues for Anavex Life Sciences....

Some eighth-grade arithmetic.

What might happen if Anavex is able to sell blarcamesine in the EU and would consequently take in $30 billion in annual revenues?

If there were an even 100 million outstanding AVXL shares, that would be a per-share annual revenue stream of $500. If, then, there were a 5% dividend dropdown (payout) that would be an annual dividend disbursement of $25 per share.

How long after Europeans benefit from blarcamesine might the drug be approved for use in the U.S.? Generally similar-sized markets, so those holding an AVXL position will be doubly-rewarded. I’ve punched the numbers for the few thousands of AVXLs I own. I and my beneficiaries will be quite pleased upon the receipt of the annual dividend check.

Of course, twice as much if the dividend dropdown were a whopping 10% of annual revenues.

Then, add in Parkinson’s, schizophrenia, analgesia, and, finally, anti-aging and geriatric disease prophylaxis. Whew...!

(And, very likely, veterinary, agricultural applications for Anavex’s sigma-1 receptor activators will be discovered and utilized.)

All worth waiting for.